Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Forcing Bioasis to Answer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Jan 16, 2023 1:49pm
122 Views
Post# 35226096

RE:RE:Forcing Bioasis to Answer

RE:RE:Forcing Bioasis to AnswerCresence was Plan B?!!!???

The Cresence people got 6 million shares or so. Those shares are now worth about $250,000. They aren't Plan B and they never were Plan B. In my opinion, they were likely part of a storyboard developed to promote this sellout.

I don't think that LT and The Placee bought Midatech and Bioasis for the Cresence stuff.

It's about xB3.

Even Stephen Stamp of Midatech is bragging about this deal and what xB3 brings to the table. You might get on the same page as he is if you want a modicum of credibility and rspect for what you're posting.

I have ask. Poof, are you being paid by any party to this deal, or anybody acting on behalf of anybody party to this deal, or anybody acting on behalf of anybody who is acting on behalf of anybody party to this deal, to pump this deal using false and misleading information?

Are you receiving any benefits from your posting about Bioasis and this deal? Because, man, it's hard to imagine anybody engaging in such a ludicrous pumpfest unless their honour and sanity is being sold to the highest bidder.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities